Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?

[1]  K. Hryniewicz,et al.  Comparative Effects of Carvedilol and Metoprolol on Regional Vascular Responses to Adrenergic Stimuli in Normal Subjects and Patients With Chronic Heart Failure , 2003, Circulation.

[2]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[3]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[4]  R. Piñeiro,et al.  Doxazosin Induces Apoptosis in Cardiomyocytes Cultured In Vitro by a Mechanism That Is Independent of &agr;1-Adrenergic Blockade , 2003, Circulation.

[5]  G. Dorn.  Adrenergic pathways and left ventricular remodeling. , 2002, Journal of cardiac failure.

[6]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[7]  B. Fagerberg,et al.  Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). , 2002, Journal of the American College of Cardiology.

[8]  P. Poole‐Wilson,et al.  Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET , 2002, European journal of heart failure.

[9]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[10]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[11]  E. Antman.  Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease , 2002 .

[12]  M. S. Täng,et al.  Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. , 2001, Journal of cardiac failure.

[13]  R. Xiao.  β-Adrenergic Signaling in the Heart: Dual Coupling of the β2-Adrenergic Receptor to Gs and Gi Proteins , 2001, Science's STKE.

[14]  B. Fagerberg,et al.  Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. , 2001, Journal of the American College of Cardiology.

[15]  A. Ducharme,et al.  Cardiac-directed overexpression of wild-type alpha1B-adrenergic receptor induces dilated cardiomyopathy. , 2001, American journal of physiology. Heart and circulatory physiology.

[16]  T. Yoshikawa,et al.  Bucindolol, a Nonselective &bgr;1‐ and &bgr;2‐Adrenergic Receptor Antagonist, Decreases &bgr;‐Adrenergic Receptor Density in Cultured Embryonic Chick Cardiac Myocyte Membranes , 2001, Journal of cardiovascular pharmacology.

[17]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[18]  W. Gattis.  Metoprolol CR/XL in the Treatment of Chronic Heart Failure , 2001, Pharmacotherapy.

[19]  L. Leinwand,et al.  Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. , 2001, The Journal of clinical investigation.

[20]  Lawrence Joseph,et al.  β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis , 2001 .

[21]  Martin G. Larson,et al.  Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?: The Framingham Heart Study , 2001, Circulation.

[22]  S. Goldstein,et al.  Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. , 2000, Journal of the American College of Cardiology.

[23]  S. Liggett.  Pharmacogenetics of Beta-1- and Beta-2-Adrenergic Receptors , 2000, Pharmacology.

[24]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[25]  A. Dilenarda,et al.  [Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure]. , 2000, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[26]  M. Raynolds,et al.  Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. , 2000, Journal of molecular and cellular cardiology.

[27]  G. Dorn,et al.  Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. , 2000, Circulation.

[28]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[29]  D. Sawyer,et al.  Adrenergic regulation of myocardial apoptosis. , 2000, Cardiovascular research.

[30]  Catherine Communal,et al.  Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .

[31]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[32]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Daniel Levy,et al.  Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. , 1999, Circulation.

[34]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[35]  M. Bristow,et al.  The role of third‐generation beta‐blocking agents in chronic heart failure , 1998, Clinical cardiology.

[36]  H. Krumholz,et al.  National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. , 1998, JAMA.

[37]  M. Bristow.  Mechanism of action of beta-blocking agents in heart failure. , 1997, The American journal of cardiology.

[38]  G. Jennings,et al.  Adrenergic nervous system in heart failure. , 1997, The American journal of cardiology.

[39]  W. Abraham,et al.  Second- and Third-Generation Beta-Blocking Drugs in Chronic Heart Failure , 1997, Cardiovascular Drugs and Therapy.

[40]  W. Abraham,et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.

[41]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[42]  M. Bristow,et al.  Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.

[43]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[44]  J. Port,et al.  Cardiac adrenergic receptor effects of carvedilol. , 1996, European heart journal.

[45]  G. Jennings,et al.  Regional epinephrine kinetics in human heart failure: evidence for extra-adrenal, nonneural release. , 1995, The American journal of physiology.

[46]  J. Wright.  Pharmacologic management of congestive heart failure. , 1995, Critical care nursing quarterly.

[47]  R. Lefkowitz,et al.  Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W. French,et al.  Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.

[49]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[50]  M. Bristow.  Changes in myocardial and vascular receptors in heart failure. , 1993, Journal of the American College of Cardiology.

[51]  M. Bristow.  Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. , 1993, The American journal of cardiology.

[52]  J. Neaton,et al.  Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. , 1993, Archives of internal medicine.

[53]  M. Böhm,et al.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.

[54]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.

[55]  R. Hershberger,et al.  Alpha-1 adrenergic receptors in the nonfailing and failing human heart. , 1988, The Journal of pharmacology and experimental therapeutics.

[56]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[57]  A. M. Lands,et al.  Differentiation of Receptor Systems activated by Sympathomimetic Amines , 1967, Nature.

[58]  P. Lundborg,et al.  Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets , 2004, European Journal of Clinical Pharmacology.

[59]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[60]  J. Wikstrand.  Achieving optimal beta1-blockade with metoprolol CR/Zok , 2000, Basic Research in Cardiology.

[61]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[62]  James D. Neaton,et al.  Serum Cholesterol, Blood Pressure, Cigarette Smoking, and Death From Coronary Heart Disease Overall Findings and Differences by Age for 316099 White Men , 1992 .

[63]  J. Port,et al.  Receptor pharmacology of carvedilol in the human heart. , 1992, Journal of cardiovascular pharmacology.

[64]  J. Neaton,et al.  Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. , 1992, Archives of internal medicine.

[65]  A. Schömig,et al.  Cardiac sympathetic activity in myocardial ischemia: release and effects of noradrenaline. , 1990, Basic research in cardiology.